Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Anakinra showed no clear difference in clinical improvement D28 compared with standard care/placebo (moderate certainty).
Anakinra may leads to lower time to WHO Clinical Progression Score of level 7 or above compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in time to death compared with standard care/placebo (low certainty).
Canakinumab showed no clear difference in clinical improvement D28 compared with standard care/placebo (moderate certainty).
The review found no eligible studies for this question.
Canakinumab showed no clear difference in WHO Clinical Progression Score of level 7 or above D28 compared with standard care/placebo (low certainty).
The review found no eligible studies for this question.
Canakinumab showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).
It is very uncertain whether canakinumab changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).
Canakinumab showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).
Canakinumab showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
It is very uncertain whether anakinra changes clinical improvement D60 or above compared with standard care/placebo (very low certainty).
Canakinumab showed no clear difference in time to clinical improvement compared with standard care/placebo (moderate certainty).
Canakinumab showed no clear difference in time to WHO Clinical Progression Score of level 7 or above compared with standard care/placebo (low certainty).
Canakinumab showed no clear difference in time to death compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in WHO Clinical Progression Score of level 7 or above D28 compared with standard care/placebo (low certainty).